Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Lumos Diagnostics Holdings Ltd. ( (AU:LDX) ).
Lumos Diagnostics reported a 12% increase in FY25 revenue, reaching US$12.4 million, despite a 26% quarterly revenue drop due to the end of the U.S. flu season. The company is advancing its FebriDx CLIA Waiver Study and has secured a significant distribution agreement with PHASE Scientific in the U.S. Additionally, Lumos has expanded its development agreement with Hologic, which is expected to generate additional revenue, and secured a loan facility to support working capital needs.
More about Lumos Diagnostics Holdings Ltd.
Lumos Diagnostics Holdings Ltd. is a leader in rapid point-of-care diagnostic technologies. The company focuses on developing and commercializing innovative diagnostic solutions, with a market emphasis on products like FebriDx® and services related to diagnostic test development and custom reader manufacturing.
Average Trading Volume: 2,835,684
Technical Sentiment Signal: Buy
Current Market Cap: A$48.65M
For detailed information about LDX stock, go to TipRanks’ Stock Analysis page.